Clotblog with Dr Samuel GoldhaberView all posts »
JUPITER deserves a standing ovationJun 29, 2010 10:37 EDT
de lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy. A critical reappraisal. Arch Intern Med. 2010; 170: 1032-1036. Available at http://archinte.ama-assn.org/
Kaul S, Morrissey RP, Diamond GA. By Jove! What is a clinician to make of JUPITER? Arch Intern Med. 2010; 170:1073-1077. Available at http://archinte.ama-assn.org/
Green LA, Cholesterol-lowering therapy for primary prevention. Still much we don't know. Arch Intern Med. 2010; 170:1007-1008. Available at http://archinte.ama-assn.org/
Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the justification for use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER). Am J Cardiol 2010; doi:10.1016/j.amjcard.2010.03.018. Available at http://ajconline.org
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein. N Engl J Med 2008; 359:2195-207.
Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of c-reactive protein. Justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER). Circulation 2010; 121: 143-150.
Glynn RJ, Danielson E, Fonseca FAH, et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-61.
Mora Samia, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity c-reactive protein or dyslipidemia. Results from the justification for the use of statins in Prevention: An intervention trial evaluation rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010; 121: 1069-1077.